Elevate Capital Advisors’s Roivant Sciences ROIV Stock Holding History

Elevate Capital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$885K	Sell	24,995 -7,155	-22%	-$211K	0.49%	41
2026 Q1	$891K	Sell	32,150 -45,395	-59%	-$1.17M	0.58%	46
2025 Q4	$1.68M	Sell	77,545 -36,236	-32%	-$715K	1.11%	37
2025 Q3	$1.72M	Sell	113,781 -2,245	-2%	-$27.8K	1.2%	39
2025 Q2	$1.31M	Sell	116,026 -61,368	-35%	-$665K	1.04%	47
2025 Q1	$1.79M	Sell	177,394 -1,459	-0.8%	-$15.8K	1.66%	23
2024 Q4	$2.12M	Buy	+178,853	New	+$2.11M	1.86%	15

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Elevate Capital Advisors's ROIV Position: Q2 2026 in Review

Elevate Capital Advisors reduced its Roivant Sciences (ROIV) stake by 22% in Q2 2026, selling an estimated $211K and leaving 24,995 shares worth $885K. The position accounts for 0.49% of the portfolio, ranked #41.

Elevate Capital Advisors first reported a position in ROIV in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.12M in Q4 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Elevate Capital Advisors held 24,995 shares of Roivant Sciences worth $885K as of Q2 2026.
Elevate Capital Advisors sold 7,155 Roivant Sciences shares in Q2 2026, an estimated $211K.
Roivant Sciences made up 0.49% of Elevate Capital Advisors's portfolio in Q2 2026, its #41 holding.
Elevate Capital Advisors first reported a position in Roivant Sciences in Q4 2024 and has held it in 7 quarters since.
Elevate Capital Advisors's Roivant Sciences position peaked at $2.12M in Q4 2024.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Elevate Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.